Ahmed M. Bayoumi




Dr. Ahmed Bayoumi is a Scientist at MAP Centre for Urban Health Solutions at the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, where he is also a general internist and Human Immunodeficiency Virus (HIV) physician. He holds the Fondation Baxter and Alma Ricard Chair in Inner City Health at St. Michael’s Hospital and the University of Toronto and is a Professor in the Department of Medicine and in the Institute of Health Policy, Management and Evaluation at the University of Toronto. He is a Senior Adjunct Scientist at ICES. He has extensive experience in translating research to policy (member of the Canadian Drug Expert Committee, past Scientific Director of Converge3, past president of the international Society for Medical Decision Making, and past Director of Clinical Epidemiology and Health Care Research at the University of Toronto). He has co-led large multi-method studies, including the highly impactful Toronto and Ottawa Supervised Consumption Assessment (TOSCA) and the Marginalization and COVID-19 (MARCO) studies. His research interests include the delivery of health services, particularly to people who use drugs, people living with HIV, and other marginalized populations. He is a member of HMRAC (the Homelessness, Mortality, Research and Advocacy Coalition), an academic – community collaboration that meets regularly to discuss how research can address issues related to homelessness.

Recent Publications

  1. Kolla, G, Khorasheh, T, Dodd, Z, Greig, S, Altenberg, J, Perreault, Y et al.. "Everybody is impacted. Everybody's hurting": Grief, loss and the emotional impacts of overdose on harm reduction workers. Int J Drug Policy. 2024;127 :104419. doi: 10.1016/j.drugpo.2024.104419. PubMed PMID:38599035 .
  2. Refaie, MMM, Amin, EF, Hassan, MN, Rifaai, RA, Bayoumi, AMA, Kamel, MY et al.. Sacubitril/valsartan protective effect on induced intestinal ischemia/reperfusion injury via immune modulation of IL6/STAT1 pathway. J Pharm Pharmacol. 2024; :. doi: 10.1093/jpp/rgae031. PubMed PMID:38538077 .
  3. Greenwald, ZR, Werb, D, Feld, JJ, Austin, PC, Fridman, D, Bayoumi, AM et al.. Validation of case-ascertainment algorithms using health administrative data to identify people who inject drugs in Ontario, Canada. J Clin Epidemiol. 2024; :111332. doi: 10.1016/j.jclinepi.2024.111332. PubMed PMID:38522754 .
  4. Ledlie, S, Tadrous, M, Bayoumi, AM, McCormack, D, Cheng, C, Besharah, J et al.. Trends in opioid toxicities among people with and without opioid use disorder and the impact of the COVID-19 pandemic in Ontario, Canada: A population-based analysis. Int J Drug Policy. 2024;127 :104392. doi: 10.1016/j.drugpo.2024.104392. PubMed PMID:38522177 .
  5. Behrends, CN, Leff, JA, Lowry, W, Li, JM, Onuoha, EN, Fardone, E et al.. Economic Evaluations of Establishing Opioid Overdose Prevention Centers in 12 North American cities: A Systematic Review. Value Health. 2024; :. doi: 10.1016/j.jval.2024.02.004. PubMed PMID:38401795 .
  6. Refaie, MMM, Mohammed, HH, Abdel-Hakeem, EA, Bayoumi, AMA, Mohamed, ZH, Shehata, S et al.. Cardioprotective role of diacerein in diabetic cardiomyopathy via modulation of inflammasome/caspase1/interleukin1β pathway in juvenile rats. Naunyn Schmiedebergs Arch Pharmacol. 2024; :. doi: 10.1007/s00210-023-02921-8. PubMed PMID:38224346 .
  7. O'Brien, KK, Erlandson, KM, Brown, DA, Carusone, SC, Vera, JH, Bergin, C et al.. Episodic disability questionnaire (EDQ) measurement properties among adults living with HIV in Canada, Ireland, United Kingdom, and United States. BMC Infect Dis. 2024;24 (1):71. doi: 10.1186/s12879-023-08958-7. PubMed PMID:38200425 PubMed Central PMC10782617.
  8. Young, S, Gomes, T, Kolla, G, McCormack, D, Dodd, Z, Raboud, J et al.. Initiations of safer supply hydromorphone increased during the COVID-19 pandemic in Ontario: An interrupted time series analysis. PLoS One. 2023;18 (12):e0295145. doi: 10.1371/journal.pone.0295145. PubMed PMID:38113220 PubMed Central PMC10729949.
  9. Hu, T, McCormack, D, Juurlink, DN, Campbell, TJ, Bayoumi, AM, Leece, P et al.. Initiation of opioid agonist therapy after hospital visits for opioid poisonings in Ontario. CMAJ. 2023;195 (49):E1709-E1717. doi: 10.1503/cmaj.231014. PubMed PMID:38110219 PubMed Central PMC10727793.
  10. Long, C, Guimond, T, Bayoumi, AM, Firestone, M, Strike, C. The multiple makings of a supervised consumption service in a hospital setting. Int J Drug Policy. 2024;123 :104260. doi: 10.1016/j.drugpo.2023.104260. PubMed PMID:38035448 .
Search PubMed

Affiliations & Other Activities

  • Scientist, MAP Centre for Urban Health Solutions, St. Michael’s Hospital
  • Professor, Department of Medicine, University of Toronto
  • Professor, Institute of Health Policy, Management and Evaluation, University of Toronto